Home
Latest
E-paper
Companies
Industry
Economy
Blueprint
Finance
Markets
Budget
India News
Politics
External Affairs Defence Security
World News
Opinion
Technology
Immigration
Specials
Partner Content
Sports
Cricket
Lifestyle
Entertainment
Social Viral
Health
BS Decoded
Books
Education
Newsletters
Web Stories
BS at 50
Multimedia
Sudoku
Crossword
BS Apps
Management
Indulgence
Premium
Explore Business Standard
BFSI Insight Summit
Events
About Us
BS Support
Popular Search
China-Plus-One strategy: Indian API firms start to reap benefits
Rising Chinese labour costs, geopolitics, pandemic-stricken uncertainties have forced global players to derisk
Dishman Group to invest $50 mn for setting up drug manufacturing facility
As part of its expansion plans, the Gujarat-headquartered drug developer will invest $50 million in France
Dishman Pharma hits new high; stock surges over 35% in two days
In past two trading days, the stock zoomed 39% from Rs 232 to Rs 322 on BSE on back of heavy volumes
Dishman Pharma hits all-time high on USFDA nod to cancer drug
Reacting to the development, the stock rallied as much as 20% to Rs 278
Dishman Pharma gains on fixing record date for bonus
The stock was up 4% at Rs 356 after the company fixed May 03, 2016 as the record date for 1:1 bonus shares.
